Harvesting of autologous peripheral blood stem cells (PBSCs) has been facilitated by using currently available, efficient apheresis technology at the time of rebound from chemotherapy while patients are receiving recombinant growth factors, i.e., granulocyte (G) or granulocyte-macrophage (GM) colony
An update on peripheral blood progenitor cell transplantation
✍ Scribed by H. Demuynck; M. Delforge; P. Zachée; G. E. G. Verhoef; P. Vandenberghe; M. A. Boogaerts
- Publisher
- Springer
- Year
- 1995
- Tongue
- English
- Weight
- 542 KB
- Volume
- 71
- Category
- Article
- ISSN
- 0939-5555
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Modest success has been achieved with the use of high-dose cytotoxic therapy and bone marrow transplantation in solid tumors. Patient outcome can potentially be improved with further intensification of the therapy. The rapid hematologic recovery achieved with mobilized peripheral blood progenitor ce
## Abstract With the advancement in apheresis technique and collection, the role of peripheral blood stem cell (PBSC) transplantation has emerged. PBSC are now being utilized either alone to reconstitute hematopoiesis following high‐dose myeloablative therapy, or in combination with autologous bone